Director Hulls Chris exercised 352,984 shares at a strike of $6.01, sold $33,480,063 worth of shares (431,749 units at $77.55) and gifted 62,500 shares, decreasing direct ownership by 30% to 335,413 units (SEC Form 4)
$LIF
EDP Services
Technology
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
Life360, Inc. [ LIF ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 11/25/2025 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock | 11/25/2025 | M | 208,987 | A | $2.15 | 685,665(1)(2) | D | |||
| Common Stock | 11/25/2025 | M | 95,833 | A | $13.35 | 781,498(1)(2) | D | |||
| Common Stock | 11/25/2025 | S | 226,556 | D | $76.91(3) | 554,942(1)(2) | D | |||
| Common Stock | 11/25/2025 | S | 80,193 | D | $77.56(4) | 474,749(1)(2) | D | |||
| Common Stock | 11/25/2025 | S | 5,000 | D | $78.38(5) | 469,749(1)(2) | D | |||
| Common Stock | 11/25/2025 | G(6) | 62,500 | D | $0 | 407,249(1)(2) | D | |||
| Common Stock | 11/26/2025 | M | 48,164 | A | $8.19 | 455,413(1)(2) | D | |||
| Common Stock | 11/26/2025 | S | 100,465 | D | $78.62(7) | 354,948(1)(2) | D | |||
| Common Stock | 11/26/2025 | S | 19,535 | D | $79.11(8) | 335,413(1)(2) | D | |||
| Common Stock | 195,312(9) | I | Held by the Robin Hulls 2023 Irrevocable Trust | |||||||
| Common Stock | 195,312(9) | I | Held by the Rose Hulls 2023 Irrevocable Trust | |||||||
| Common Stock | 195,312(9) | I | Held by the Mckenzie Hulls 2023 Irrevocable Trust | |||||||
| Common Stock | 1,846(10) | I | Held by ICCA Labs, LLC | |||||||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Stock Option (right to buy) | $2.15 | 11/25/2025 | M | 208,987 | (11) | 10/24/2027 | Common Stock | 208,987 | $0 | 0 | D | ||||
| Stock Option (right to buy) | $13.35 | 11/25/2025 | M | 95,833 | (11) | 02/01/2027 | Common Stock | 95,833 | $0 | 4,167 | D | ||||
| Stock Option (right to buy) | $8.19 | 11/26/2025 | M | 48,164 | (12) | 05/20/2028 | Common Stock | 48,164 | $0 | 233,801 | D | ||||
| Explanation of Responses: |
| 1. Includes common stock and the number of shares of common stock underlying Chess Depositary Interests ("CDIs") as converted on a 1:3 common stock to CDI ratio. The CDIs are traded on the Australian Securities Exchange (the "ASX") and are held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. |
| 2. Includes 137,853 restricted stock units previously granted, each of which represents a contingent right to receive one share of the Issuer's common stock upon vesting. |
| 3. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $76.25 to $77.245, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full details regarding the number of shares sold at each separate price within the range. |
| 4. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $77.25 to $78.21, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full details regarding the number of shares sold at each separate price within the range. |
| 5. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $78.32 to $78.43, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full details regarding the number of shares sold at each separate price within the range. |
| 6. This transaction reflects a bona fide gift of the Issuer's stock to a donor-advised fund (DAF) for charitable purposes. The Reporting Person retains no beneficial ownership or control over the donated securities following the contribution. |
| 7. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $78.02 to $79.015, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full details regarding the number of shares sold at each separate price within the range. |
| 8. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $79.02 to $79.34, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full details regarding the number of shares sold at each separate price within the range. |
| 9. Represents shares of the Issuer's common stock underlying 585,938 CDIs. |
| 10. The Reporting Person is a member of ICCA Labs, LLC, an entity that holds an aggregate of 8,219 shares of the Issuer's common stock. The number of shares held as reported herein by the Reporting Person represents his proportionate ownership interest in ICCA Labs, LLC. |
| 11. The stock option is fully vested and exercisable. |
| 12. The stock option vests and becomes exercisable as to 1/48th of the total number of shares in equal monthly installments beginning on February 1, 2022, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. |
| Remarks: |
| The vesting terms for the stock option with an exercise price of $8.19 reported herein were inadvertently misreported on the Reporting Person's Form 3/A filed on July 20, 2022, and have been corrected as of this Form 4. |
| /s/ Jay Sood, Attorney-in-Fact | 11/26/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||